JP Morgan Chase
CUE icon

JP Morgan Chase’s Cue Biopharma CUE Stock Holding History

JP Morgan Chase’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-440
Closed -$33K – 6512
2022
Q2 		$33K Hold
440
– – ﹤0.01% 5771
2022
Q1 		$64K Hold
440
– – ﹤0.01% 5696
2021
Q4 		$149K Buy
+440
New +$170K ﹤0.01% 5499

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $1.84B AUM 19.34% 1-Year Est. Return

JP Morgan Chase's CUE Position: Q1 2026 in Review

JP Morgan Chase held its Cue Biopharma (CUE) position steady in Q1 2026 at 0 shares worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #7475.

JP Morgan Chase first reported a position in CUE in Q1 2018 and has held it in 31 quarters since. The position peaked at $229K in Q2 2020. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • JP Morgan Chase held 0 shares of Cue Biopharma worth $1 as of Q1 2026.
  • JP Morgan Chase left its Cue Biopharma share count unchanged in Q1 2026.
  • Cue Biopharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7475 holding.
  • JP Morgan Chase first reported a position in Cue Biopharma in Q1 2018 and has held it in 31 quarters since.
  • JP Morgan Chase's Cue Biopharma position peaked at $229K in Q2 2020.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.